Jubilant Pharmova share price
You have to be logged in to add this to Watchlist.- ₹1,156.90(-1.16%)July 11, 2025 15:29:25 PM IST
- NSE
- BSE
- Vol : 146.52K (NSE + BSE)Last 20 day avg : 406.58 K
Jubilant Pharmova is trading -1.16% lower at Rs 1,156.90 as compared to its last closing price. Jubilant Pharmova has been trading in the price range of 1,183.10 & 1,150.05. Jubilant Pharmova has given 6.03% in this year & -2.47% in the last 5 days. Jubilant Pharmova has TTM P/E ratio 16.91 as compared to the sector P/E of 22.90.There are 3 analysts who have initiated coverage on Jubilant Pharmova. There are - analysts who have given it a strong buy rating & - analysts have given it a buy rating. - analysts have given the stock a sell rating.The company posted a net profit of 153.60 Crores in its last quarter.Listed peers of Jubilant Pharmova include Eris Lifesciences (-0.54%), Alembic Pharmaceuticals (-0.21%), Jubilant Pharmova (-1.16%).The Mutual Fund holding in Jubilant Pharmova was at 3.66% in 31 Mar 2025. The MF holding has increased from the last quarter. The FII holding in Jubilant Pharmova was at 17.23% in 31 Mar 2025. The FII holding has increased from the last quarter.
- Overview
- Financials
- Forecast
- Technical Analysis
- Peers
- Shareholding
- About the company
- FAQ
Overview
Updated on Jul 12, 2025, 06:36 AM UTC
- Dividend YieldLower than industry0.42Annual dividends as a percentage of the stock price.
- P/BLower than historical values3.02The P/B ratio shows how a stock's market price compares to its book value. It helps gauge whether a stock is undervalued or overvalued relative to its net assets.
- P/ELower than historical values22.55Price-to-earnings ratio based on trailing 12-month earnings
- BetaMedium volatility0.96Beta measures a stock's volatility compared to the overall market. A beta > 1 indicates higher volatility than the market.
- Debt To EquityHigher than industry0.44The debt-to-equity ratio, indicating a company's financial leverage.
- PEG Ratio-The PEG ratio evaluates a stock's valuation by comparing its P/E ratio to its earnings growth rate. A lower PEG suggests better value relative to growth
|
| ||||
|
| ||||
- Income
- Balance Sheet
- Cash Flow
- Financial
- Valuation
Company is profitable- The company's revenue grew in March quarter by 9.68% from Rs 1928.80 crore to Rs 1758.60 crore, year-on-year
- Company has registered a profit of 153.60 cr vs a loss of 58.60 cr in the same quarter last year.
The debt to equity of the company is higher than the industry median- Company can comfortably pay off its interest obligations with its earnings
- R1
- 1,246.37
- R2
- 1,283.53
- R3
- 1,334.22
- S1
- 1,158.52
- S2
- 1,107.83
- S3
- 1,070.67
- Very Bearish
- Bearish
- Neutral
- Very Bullish
- Bullish
Names | Technical rating | Price | %Change | Market Cap | P/E | P/B | Dividend Yield | Debt to Equity |
|---|---|---|---|---|---|---|---|---|
| Eris Lifesciences | Bullish | 1,728.00 | -0.54 | 23,733.68 | 66.44 | 8.2 | 0.43 | 62.42 |
| Alembic Pharmaceuticals | Neutral | 975.00 | -0.21 | 19,165.87 | 34.73 | 3.81 | 1.09 | 0.90 |
| Jubilant Pharmova | Neutral | 1,156.90 | -1.16 | 18,427.23 | 35.82 | 3.04 | 0.42 | 38.19 |
| Natco Pharma | Moderately Bullish | 961.75 | -3.65 | 17,225.89 | 9.25 | 2.29 | 0.62 | 0.06 |
| Caplin Point Laboratories | Moderately Bearish | 2,018.20 | -1.17 | 15,394.47 | 28.50 | 5.33 | 0.27 | 0.10 |
- Promoter(s) holds a high stake in the company at 50.68%
- FIIs are invested in this company
- FIIs holding has increased by 0.27 percentage points from previous quarter
- Mutual Funds holding has increased by 0.02 percentage points from previous quarter
- Board Meetings
- AGM
- Dividends
- Bonus
- Split
- Rights
| Meeting Date | Purpose |
|---|---|
| 2025-05-16 | Audited Results & Final Dividend |
| 2025-01-31 | Quarterly Results |
| 2024-10-25 | Quarterly Results |
| 2024-07-19 | Quarterly Results |
| 2024-05-29 | Audited Results & Final Dividend |
- IndustryBiotechnology & Drugs
- ISININE700A01033
- BSE Code530019
- NSE CodeJUBLPHARMA
Jubilant Pharmova is trading at 1156.90 as on Fri Jul 11 2025 09:59:25. This is -1.16% lower as compared to its previous closing price of 1170.50.
The market capitalization of Jubilant Pharmova is 18427.23 Cr as on Fri Jul 11 2025 09:59:25.
The 52 wk high for Jubilant Pharmova is 1309.00 whereas the 52 wk low is 701.40
Jubilant Pharmova can be analyzed on the following key metrics -
- TTM P/E: 16.91
- Sector P/E: 22.90
- Dividend Yield: 0.43%
- D/E ratio: 0.44
Jubilant Pharmova reported a net profit of 839.40 Cr in 2025.
The Mutual Fund Shareholding was 3.66% at the end of 31 Mar 2025.